Interferon alpha-2b biobetter - HanAll Biopharma

Drug Profile

Interferon alpha-2b biobetter - HanAll Biopharma

Alternative Names: Hanferon; HL031 (oral interferon alpha-2b) - HanAll Biopharma; HL143 (subcutaneous interferon alpha-2b) - HanAll Biopharma; Modified interferon-alpha - HanAll Biopharma; Resis-IFN-alpha-2b

Latest Information Update: 11 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nautilus Biotech
  • Developer HanAll Biopharma; Nautilus Biotech
  • Class Antivirals; Biobetters; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer; Hepatitis C; Liver cancer

Most Recent Events

  • 11 Sep 2017 Discontinued - Phase-II for Hepatitis C in USA (SC)
  • 11 Sep 2017 Discontinued - Phase-II for liver cancer (Prevention of relapse) in USA (SC)
  • 17 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top